Literature DB >> 26091988

Clinical outcomes of no residual disease in the specimen after endoscopic resection for gastric neoplasms.

Ji Min Choi1, Sang Gyun Kim2, Hyo-Joon Yang3, Joo Hyun Lim4, Jeongmin Choi1, Jong Pil Im1, Joo Sung Kim1, Woo Ho Kim5, Hyun Chae Jung1.   

Abstract

BACKGROUND: No residual disease (NRD) can be found in the specimen after endoscopic resection (ER) of biopsy-proven gastric neoplasm. This study aimed to evaluate the endoscopic and pathologic characteristics of patients with NRD and identify the cause and long-term prognosis.
METHODS: Medical records of patients who underwent ER for biopsy-proven gastric neoplasms at a single tertiary hospital between January 2005 and November 2014 were retrospectively reviewed. Patients whose post-ER histology was revealed as NRD were included. Overall incidence, clinicopathologic characteristics, cause, and long-term prognosis were analyzed.
RESULTS: NRD was detected in 143 (3.2%) of 4401 cases of gastric neoplasms treated with ER. Mean endoscopic size of the initial lesion was 8.15 ± 6.64 mm; in 93 cases (65.0%), the lesion was located in the lower third of the stomach. Initial pathologic diagnosis was as follows: adenoma (n = 110), carcinoma (n = 29), and atypical gland (n = 4). The causes of NRD were minute lesions removed by biopsy in 140 patients, pathologic misdiagnoses in two, and localization error in one. Local recurrence was detected in five patients (3.6%) with minute lesions during follow-up and treated with argon plasma coagulation (n = 4) or re-ER (n = 1). Synchronous (n = 5, 3.6%) and metachronous gastric lesions (n = 6, 4.3%) were also detected during follow-up.
CONCLUSIONS: The main cause of NRD was minute lesions which might be completely removed by initial diagnostic biopsy. These cases showed a minimal rate of local recurrence and synchronous or metachronous gastric neoplasms. Careful follow-up is also mandatory for detection of residual disease.

Entities:  

Keywords:  Biopsy; Endoscopy resection; Residual disease; Stomach neoplasms

Mesh:

Year:  2015        PMID: 26091988     DOI: 10.1007/s00464-015-4248-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  25 in total

Review 1.  The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002.

Authors: 
Journal:  Gastrointest Endosc       Date:  2003-12       Impact factor: 9.427

Review 2.  Endoscopic submucosal dissection of early gastric cancer.

Authors:  Masaki Tanaka; Hiroyuki Ono; Noriaki Hasuike; Kohei Takizawa
Journal:  Digestion       Date:  2008-01-18       Impact factor: 3.216

3.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

4.  Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study.

Authors:  S M Muehldorfer; M Stolte; P Martus; E G Hahn; C Ell
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

5.  Multiple primary malignant neoplasms: historical perspectives.

Authors:  C G Moertel
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

6.  Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions.

Authors:  H Inoue; K Takeshita; H Hori; Y Muraoka; H Yoneshima; M Endo
Journal:  Gastrointest Endosc       Date:  1993 Jan-Feb       Impact factor: 9.427

7.  Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.

Authors:  Takuji Gotoda; Akio Yanagisawa; Mitsuru Sasako; Hiroyuki Ono; Yukihiro Nakanishi; Tadakazu Shimoda; Yo Kato
Journal:  Gastric Cancer       Date:  2000-12       Impact factor: 7.370

8.  [Clinicopathologic features of cases with negative pathologic results after endoscopic submucosal dissection].

Authors:  Min-Jung Kwon; Jong-Jae Park; Jae-Won Yun; Hye Jin Noh; Dae Woong Yoon; Won Jin Chang; Ha Young Oh; Baek-Hui Kim; Hyunjoo Lee; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jae Seon Kim; Kwan Soo Byun; Young-Tae Bak
Journal:  Korean J Gastroenterol       Date:  2012-03

Review 9.  Assessing risks for gastric cancer: new tools for pathologists.

Authors:  Robert M Genta; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 10.  [Gastric cancer screening and diagnosis].

Authors:  Il Ju Choi
Journal:  Korean J Gastroenterol       Date:  2009-08
View more
  5 in total

1.  Clinical features of negative pathologic results after gastric endoscopic submucosal dissection.

Authors:  Dong Il Jeong; Hyung Wook Kim; Cheol Woong Choi; Dae Hwan Kang; Su Bum Park; Su Jin Kim; Hyeong Seok Nam
Journal:  Surg Endosc       Date:  2016-07-12       Impact factor: 4.584

2.  Clinicopathologic Characteristics and Long-Term Outcome of Gastric Cancer Patients with Family History: Seven-Year Follow-Up Study for Korean Health Check-Up Subjects.

Authors:  Jooyoung Lee; Su Jin Chung; Ji Min Choi; Yoo Min Han; Joo Sung Kim
Journal:  Gastroenterol Res Pract       Date:  2020-10-22       Impact factor: 2.260

3.  Predictors of upstage diagnosis after endoscopic resection of gastric low-grade dysplasia.

Authors:  Dae Hwan Kang; Cheol Woong Choi; Hyung Wook Kim; Su Bum Park; Su Jin Kim; Hyeong Seok Nam; Dae Gon Ryu
Journal:  Surg Endosc       Date:  2017-12-06       Impact factor: 4.584

4.  Negative pathology after endoscopic resection of gastric epithelial neoplasms: importance of pit dysplasia.

Authors:  Joon Hyung Jhi; Gwang Ha Kim; Ahrong Kim; Young-Geum Kim; Cheong Su Hwang; Sojeong Lee; Bong Eun Lee; Geun Am Song; Do Youn Park
Journal:  Korean J Intern Med       Date:  2017-01-20       Impact factor: 2.884

5.  Predictive Model of Nonneoplastic Pathology after Endoscopic Resection of Gastric Epithelial Neoplasia.

Authors:  Tae-Geun Gweon; Byung-Wook Kim; Joon Sung Kim; Sung Min Park; Jeong Seon Ji; Bo In Lee
Journal:  Gut Liver       Date:  2020-03-15       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.